title: Valproic acid, an anti-epileptic drug and a histone deacetylase inhibitor, in combination with proteasome inhibitors exerts antiproliferative, pro-apoptotic and chemosensitizing effects in human colorectal cancer cells: underlying molecular mechanisms.
abstract: Although the therapeutic efficacy of valproic acid (VPA) has been observed in patients with solid tumors, the very high concentration required to induce antitumor activity limits its clinical utility. The present study focused on the development of combined molecular targeted therapies using VPA and proteasome inhibitors (PIs: MG132, PI-1 and PR-39) to determine whether this combination of treatments has synergistic anticancer and chemosensitizing effects against colorectal cancer. Furthermore, the potential molecular mechanisms of action of the VPA/PI combinations were evaluated. The effects of VPA in combination with PIs on the growth of colorectal cancer cells were assessed with regard to proliferation, cell cycle, apoptosis, reactive oxygen species (ROS) generation and the expression of genes that control the cell cycle, apoptosis and pro-survival/stress-related pathways. Treatment with combinations of VPA and PIs resulted in an additive/synergistic decrease in colorectal cancer cell proliferation compared to treatment with VPA or PIs alone. The combination treatment was associated with a synergistic increase in apoptosis and in the number of cells arrested in the S phase of the cell cycle. These events were associated with increased ROS generation, pro-apoptotic gene expression and stress-related gene expression. These events were also associated with the decreased expression of anti-apoptotic genes and pro-survival genes. The combination of VPA with MG132 or PI-1 enhanced the chemosensitivity of the SW1116 (29-185‑fold) and SW837 (50-620-fold) colorectal cancer cells. By contrast, the combination of VPA/PR-39 induced a pronounced increase in the chemosensitivity of the SW837 (16-54-fold) colorectal cancer cells. These data provide a rational basis for the clinical use of this combination therapy for the treatment of colorectal cancer.
authors.affiliation: Department of Biological Sciences, Faculty of Science, Kuwait University, Safat 13060, Kuwait.
authors.forename: Mohamed-Salah I
authors.initials: MS
authors.lastname: Abaza
authors.affiliation: Department of Biological Sciences, Faculty of Science, Kuwait University, Safat 13060, Kuwait.
authors.forename: Abdul-Majeed
authors.initials: AM
authors.lastname: Bahman
authors.affiliation: Department of Microbiology, Faculty of Medicine, Kuwait University, Safat 13060, Kuwait.
authors.forename: Raja'a J
authors.initials: RJ
authors.lastname: Al-Attiyah
mesh_terms: D000927:Anticonvulsants / Q000008:administration & dosage; D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D004357:Drug Synergism; D056572:Histone Deacetylase Inhibitors / Q000008:administration & dosage; D006801:Humans; D017382:Reactive Oxygen Species / Q000378:metabolism; D014635:Valproic Acid / Q000008:administration & dosage*
chemical_list: D000927:Anticonvulsants; D056572:Histone Deacetylase Inhibitors; D017382:Reactive Oxygen Species; D014635:Valproic Acid